Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay
Posted inHematology-Oncology news Oncology

Real-World Impact of Post-Treatment Circulating Tumor DNA Monitoring in Large B-Cell Lymphoma Using an Immunoglobulin-Based Assay

This study demonstrates that detection of circulating tumor DNA (ctDNA) after treatment in large B-cell lymphoma predicts progression-free survival, highlighting the clinical utility of a rapid immunoglobulin rearrangement-targeted assay for measurable residual disease assessment in real-world settings.